Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts. Show more

101 Main Street, Cambridge, MA, 02142, United States

Biotechnology
Healthcare

Market Cap

1.171B

52 Wk Range

$23.00 - $36.61

Previous Close

$25.08

Open

$24.89

Volume

184,433

Day Range

$23.81 - $25.74

Enterprise Value

1.011B

Cash

163.5M

Avg Qtr Burn

-21.58M

Insider Ownership

10.78%

Institutional Own.

59.91%

Qtr Updated

03/31/26